Latest Ludwig Institute Stories
NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20).
New technique reveals functional gene networks in a live organism.
NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC).
Findings help illuminate biochemical mechanisms that determine stem cell function and fate.
Modern genotyping technologies offer new opportunities to explore how genes influence health and disease, but also present the challenge of analyzing huge amounts of genetic and clinical data.
ROCKVILLE, Md. and NEW YORK, Jan. 27 /PRNewswire-USNewswire/ -- Researchers from the J.
Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have identified a key step required for cell division in a study that could help improve therapies to treat cancer.
ANN ARBOR, Mich., June 22 /PRNewswire-USNewswire/ -- For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke.
Scientists from the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR) have made a promising discovery that could improve the early diagnosis of breast and ovarian cancers through a simple blood test.
- Growing in low tufty patches.